» Articles » PMID: 30462529

Macrophage FABP4 is Required for Neutrophil Recruitment and Bacterial Clearance in Pseudomonas Aeruginosa Pneumonia

Overview
Journal FASEB J
Specialties Biology
Physiology
Date 2018 Nov 22
PMID 30462529
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Fatty acid binding protein 4 (FABP4), an intracellular lipid chaperone and adipokine, is expressed by lung macrophages, but the function of macrophage-FABP4 remains elusive. We investigated the role of FABP4 in host defense in a murine model of Pseudomonas aeruginosa pneumonia. Compared with wild-type (WT) mice, FABP4-deficient (FABP4) mice exhibited decreased bacterial clearance and increased mortality when challenged intranasally with P. aeruginosa. These findings in FABP4 mice were associated with a delayed neutrophil recruitment into the lungs and were followed by greater acute lung injury and inflammation. Among leukocytes, only macrophages expressed FABP4 in WT mice with P. aeruginosa pneumonia. Chimeric FABP4 mice with WT bone marrow were protected from increased mortality seen in chimeric WT mice with FABP4 bone marrow during P. aeruginosa pneumonia, thus confirming the role of macrophages as the main source of protective FABP4 against that infection. There was less production of C-X-C motif chemokine ligand 1 (CXCL1) in FABP4 alveolar macrophages and lower airway CXCL1 levels in FABP4 mice. Delivering recombinant CXCL1 to the airways protected FABP4 mice from increased susceptibility to P. aeruginosa pneumonia. Thus, macrophage-FABP4 has a novel role in pulmonary host defense against P. aeruginosa infection by facilitating crosstalk between macrophages and neutrophils via regulation of macrophage CXCL1 production.-Liang, X., Gupta, K., Rojas Quintero, J., Cernadas, M., Kobzik, L., Christou, H., Pier, G. B., Owen, C. A., Çataltepe, S. Macrophage FABP4 is required for neutrophil recruitment and bacterial clearance in Pseudomonas aeruginosa pneumonia.

Citing Articles

Research Progress on the Immune Function of Liver Sinusoidal Endothelial Cells in Sepsis.

Wang X, Guo Z, Xia Y, Wang X, Wang Z Cells. 2025; 14(5).

PMID: 40072101 PMC: 11899273. DOI: 10.3390/cells14050373.


Immunometabolic reprogramming in macrophages infected with active and dormant : differential modulation of respiration, glycolysis, and fatty acid utilization.

Marina C, de Castro R, Bellozi P, Cruz A, Burgel P, Potter P Infect Immun. 2024; 93(2):e0048724.

PMID: 39714095 PMC: 11834436. DOI: 10.1128/iai.00487-24.


Adipokines: masterminds of metabolic inflammation.

Tilg H, Ianiro G, Gasbarrini A, Adolph T Nat Rev Immunol. 2024; .

PMID: 39511425 DOI: 10.1038/s41577-024-01103-8.


The gut microbiota and its metabolite butyrate shape metabolism and antiviral immunity along the gut-lung axis in the chicken.

Saint-Martin V, Guillory V, Chollot M, Fleurot I, Kut E, Roesch F Commun Biol. 2024; 7(1):1185.

PMID: 39300162 PMC: 11413219. DOI: 10.1038/s42003-024-06815-0.


The role of fatty acid metabolism in acute lung injury: a special focus on immunometabolism.

Lu X, Li G, Liu Y, Luo G, Ding S, Zhang T Cell Mol Life Sci. 2024; 81(1):120.

PMID: 38456906 PMC: 10923746. DOI: 10.1007/s00018-024-05131-4.


References
1.
Ghosh S, Gregory D, Smith A, Kobzik L . MARCO regulates early inflammatory responses against influenza: a useful macrophage function with adverse outcome. Am J Respir Cell Mol Biol. 2011; 45(5):1036-44. PMC: 3262690. DOI: 10.1165/rcmb.2010-0349OC. View

2.
Ghelfi E, Karaaslan C, Berkelhamer S, Akar S, Kozakewich H, Cataltepe S . Fatty acid-binding proteins and peribronchial angiogenesis in bronchopulmonary dysplasia. Am J Respir Cell Mol Biol. 2010; 45(3):550-6. PMC: 3175587. DOI: 10.1165/rcmb.2010-0376OC. View

3.
Gaspar M, Couet W, Olivier J, Pais A, Sousa J . Pseudomonas aeruginosa infection in cystic fibrosis lung disease and new perspectives of treatment: a review. Eur J Clin Microbiol Infect Dis. 2013; 32(10):1231-52. DOI: 10.1007/s10096-013-1876-y. View

4.
Makowski L, Boord J, Maeda K, Babaev V, Uysal K, Morgan M . Lack of macrophage fatty-acid-binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis. Nat Med. 2001; 7(6):699-705. PMC: 4027052. DOI: 10.1038/89076. View

5.
Burak M, Inouye K, White A, Lee A, Tuncman G, Calay E . Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. Sci Transl Med. 2015; 7(319):319ra205. DOI: 10.1126/scitranslmed.aac6336. View